NIH funds liver damage studies
This article was originally published in The Tan Sheet
Patients suffering severe liver damage from OTC or Rx drugs, nutritional supplements, alternative medicines and herbals will be studied over the next three years in a "network" of five clinical centers and one data coordinating center, NIH announces Nov. 19. The five drug-induced liver injury (DILIN) centers - in North Carolina, Indiana, San Francisco, Michigan and Connecticut - will each receive $2.25 mil. annually from NIH. The DILIN study will follow patients who recently suffered an adverse liver reaction from a drug in order to "find out what happens to them as a result of their injury" and will "develop standardized definitions" to identify cases of liver damage...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”